Abstract
Arterial hypertension (HPT) burden up to two third of systemic lupus erythematosus (SLE) patients and contributes to accelerated atherosclerosis and cardiovascular (CV) risk. We aim to determine the prevalence of HPTamong lupus nephritis (LN) patients who were in complete remission (CR) for a minimum of 6 months, with estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73 m<sup>2</sup>. This is a cross-sectional study of 64 LN patients who attended Nephrology/ SLE Clinic at The National University of Malaysia Medical Centre (UKMMC). Persistent hypertension (blood pressure (BP) ≥140/90 mmHg for at least two occasions), CR for a minimum of 6 months and eGFR of >60 mL/min/1.73 m<sup>2</sup> were identified. Univariate and multivariate analyses were performed to determine the demographic and disease characteristics associated with HPT. Thirty-four of them (53.1%) were hypertensive. Persistent HPT was associated with disease duration, acute kidney injury and high BP at the onset of LN, longer duration interval to achieve CR, number of relapses and cyclosporine A (CyA) use. There were no associations between histological classes, nephrotic range proteinuria, body mass index and waist circumference with HPT. Factors independently associated with HPT were disease duration OR 1.06 [95%CI (0.91–1.24)], longer duration interval to achieve CR OR 1.104 [95%CI (1.02–1.19)], number of relapses OR 2.53 [95% CI (1.01–6.3)] and CyA use OR 5.3 [95% CI (1.14–23.9)]. The prevalence of HPT among LN is high despite in remission. Aggressive treatment is important to achieve early CR and to prevent relapses.
| Original language | English |
|---|---|
| Article number | A093 |
| Pages (from-to) | 93-97 |
| Number of pages | 5 |
| Journal | Clinical Rheumatology |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Cyclosporine A
- Hypertension
- Lupus nephritis
- Remission
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology
- Medicine(all)
Cite this
Persistent hypertension in lupus nephritis and the associated risk factors. / Shaharir, Syahrul Sazliyana; Mustafar, Ruslinda; Mohd, Rozita; Mohamed Said, Mohd Shahrir; Abdul Gafor, Abdul Halim.
In: Clinical Rheumatology, Vol. 34, No. 1, A093, 2015, p. 93-97.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Persistent hypertension in lupus nephritis and the associated risk factors
AU - Shaharir, Syahrul Sazliyana
AU - Mustafar, Ruslinda
AU - Mohd, Rozita
AU - Mohamed Said, Mohd Shahrir
AU - Abdul Gafor, Abdul Halim
PY - 2015
Y1 - 2015
N2 - Arterial hypertension (HPT) burden up to two third of systemic lupus erythematosus (SLE) patients and contributes to accelerated atherosclerosis and cardiovascular (CV) risk. We aim to determine the prevalence of HPTamong lupus nephritis (LN) patients who were in complete remission (CR) for a minimum of 6 months, with estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73 m2. This is a cross-sectional study of 64 LN patients who attended Nephrology/ SLE Clinic at The National University of Malaysia Medical Centre (UKMMC). Persistent hypertension (blood pressure (BP) ≥140/90 mmHg for at least two occasions), CR for a minimum of 6 months and eGFR of >60 mL/min/1.73 m2 were identified. Univariate and multivariate analyses were performed to determine the demographic and disease characteristics associated with HPT. Thirty-four of them (53.1%) were hypertensive. Persistent HPT was associated with disease duration, acute kidney injury and high BP at the onset of LN, longer duration interval to achieve CR, number of relapses and cyclosporine A (CyA) use. There were no associations between histological classes, nephrotic range proteinuria, body mass index and waist circumference with HPT. Factors independently associated with HPT were disease duration OR 1.06 [95%CI (0.91–1.24)], longer duration interval to achieve CR OR 1.104 [95%CI (1.02–1.19)], number of relapses OR 2.53 [95% CI (1.01–6.3)] and CyA use OR 5.3 [95% CI (1.14–23.9)]. The prevalence of HPT among LN is high despite in remission. Aggressive treatment is important to achieve early CR and to prevent relapses.
AB - Arterial hypertension (HPT) burden up to two third of systemic lupus erythematosus (SLE) patients and contributes to accelerated atherosclerosis and cardiovascular (CV) risk. We aim to determine the prevalence of HPTamong lupus nephritis (LN) patients who were in complete remission (CR) for a minimum of 6 months, with estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73 m2. This is a cross-sectional study of 64 LN patients who attended Nephrology/ SLE Clinic at The National University of Malaysia Medical Centre (UKMMC). Persistent hypertension (blood pressure (BP) ≥140/90 mmHg for at least two occasions), CR for a minimum of 6 months and eGFR of >60 mL/min/1.73 m2 were identified. Univariate and multivariate analyses were performed to determine the demographic and disease characteristics associated with HPT. Thirty-four of them (53.1%) were hypertensive. Persistent HPT was associated with disease duration, acute kidney injury and high BP at the onset of LN, longer duration interval to achieve CR, number of relapses and cyclosporine A (CyA) use. There were no associations between histological classes, nephrotic range proteinuria, body mass index and waist circumference with HPT. Factors independently associated with HPT were disease duration OR 1.06 [95%CI (0.91–1.24)], longer duration interval to achieve CR OR 1.104 [95%CI (1.02–1.19)], number of relapses OR 2.53 [95% CI (1.01–6.3)] and CyA use OR 5.3 [95% CI (1.14–23.9)]. The prevalence of HPT among LN is high despite in remission. Aggressive treatment is important to achieve early CR and to prevent relapses.
KW - Cyclosporine A
KW - Hypertension
KW - Lupus nephritis
KW - Remission
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=84939793763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939793763&partnerID=8YFLogxK
U2 - 10.1007/s10067-014-2802-0
DO - 10.1007/s10067-014-2802-0
M3 - Article
VL - 34
SP - 93
EP - 97
JO - Clinical Rheumatology
JF - Clinical Rheumatology
SN - 0770-3198
IS - 1
M1 - A093
ER -